▎药明康德内容团队编辑
▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放
参考资料：
[1] Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy. Retrieved December 2, 2024, from https://www.globenewswire.com/news-release/2024/12/02/2989688/35409/en/Cytokinetics-Announces-FDA-Acceptance-of-New-Drug-Application-for-Aficamten-for-the-Treatment-of-Obstructive-Hypertrophic-Cardiomyopathy.html
[2] Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine. Retrieved May 13, 2024, from https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-primary-results-sequoia-hcm-presented
免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。
版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。
分享，点赞，在看，聚焦全球生物医药健康创新
